A reference human induced pluripotent stem cell line for large-scale collaborative studies
National Institutes of Health · National Institute of Neurological Disorders and Stroke · +48 more institutions
Abstract
Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines makes it challenging to replicate key findings and integrate data across research groups. To address this issue, we sub-cloned candidate human iPSC lines and deeply characterized their genetic properties using whole genome sequencing, their genomic stability upon CRISPR-Cas9-based gene editing, and their phenotypic properties including differentiation to commonly used cell types. These studies identified KOLF2.1J as an all-around well-performing iPSC line. We then shared KOLF2.1J with groups around the world who tested its performance in head-to-head…
Citation impact
- FWCI
- 22.44
- Percentile
- 100%
- References
- 117
Authors
95- CBCaroline B. Pantazis
National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging
- AYAndrian Yang
European Bioinformatics Institute, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Cancer Research UK, Wellcome/MRC Institute of Metabolic Science, Wellcome Trust, Medical Research Council
- ELErika Lara
National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging
- JAJustin A. McDonough
Jackson Laboratory
- CBCornelis Blauwendraat
National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging
Topics & keywords
- Biology
- Induced pluripotent stem cell
- Computational biology
- CRISPR
- Genome editing
- Phenotype
- Stem cell
- Cas9
Funding
- UDU.S. Department of Health and Human ServicesAward: ZO1 AG000535
- CICalifornia Institute for Regenerative MedicineAward: EDUC4-12812
- NYNew York Stem Cell FoundationAwards: NYSCF-R-156, C32561GG, NYSCF-I-R44
- NYNew York State Department of HealthAward: NYSTEM-C32561GG
- AFAlzheimer Forschung Initiative
- WTWellcome TrustAward: 211221/Z/18/Z
- EBEuropean Bioinformatics InstituteAward: C9545/A29580
- NYNew York State Stem Cell ScienceAwards: C32561GG, NYSTEM-C32561GG
- TATarget ALS
- EMEuropean Molecular Biology Laboratory
- IMInternational Max Planck Research School for Environmental, Cellular and Molecular Microbiology
- CRCancer Research UKAwards: EU H2020, C9545, C9545/A29580
- NINational Institute for Health and Care ResearchAward: MR/R015724/1
- UCUniversity College London
- DFDeutsche ForschungsgemeinschaftAwards: EXC 2145, 471227244, ID 390857198, 390857198, EXC 2145 SyNergy
- ZZonMw
- CCancerfondenAward: CAN2016/572
- FWFonds Wetenschappelijk Onderzoek
- NONederlandse Organisatie voor Wetenschappelijk Onderzoek
- KIKarolinska InstitutetAward: 2020-01426
- SDStudienstiftung des Deutschen Volkes
- UAUniversiteit Antwerpen
- VRVlaamse regering
- IMInternational Max Planck Research School for Advanced Methods in Process and Systems Engineering
- NINational Institutes of HealthAwards: ZO1 AG000535, T32-AG-000255, F32NS114319, NS060698, R01NS117461, T32 NS115706, W81XWH, NS27036, R01 NS060698, R01-NS27036, H2020
- H2Horizon 2020 Framework ProgrammeAwards: 899687, H2020-MSCA, 813851, MSCA-ITN-2018, EU H2020, H2020-MSCA-ITN-2018, H2020-MSCA-ITN
- NDNational Defense Science and Engineering Graduate
- MRMedical Research CouncilAwards: MR/R015724/1, MR/R015724/1
- CRCancer Research UK Cambridge Institute, University of CambridgeAwards: A29580, C9545/A29580
- NINational Institute on AgingAwards: ZO1 AG000535, T32AG066596, AG000535
- NINational Institute of Neurological Disorders and StrokeAwards: R01NS117461, T32 NS115706, F32NS114319, R01-NS27036, 33601, NS060698, ZO1 AG000535, NS27036, R01 NS060698